After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched pairs of ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler ... or severe COPD exacerbation (effectiveness) and first admission to ...

Triple therapy of an inhaled corticosteroid ... with chronic obstructive pulmonary disease (COPD), a history of exacerbations, and high symptom burden in pivotal randomised trials.1234 However, this ...